Recombinant Albumin Market Poised to Reach USD 1.95 Billion by 2032 on Back of Rising Biopharmaceutical Demand

Market Intelo has released a comprehensive analysis of the global Recombinant Albumin market, positioned within the “Healthcare” parent category and the “Healthcare & Pharmaceuticals” child segment. The report indicates that the market was valued at USD 920 million in 2023 and is projected to reach USD 1.95 billion by 2032, growing at a CAGR of 8.4% during the forecast period. Increasing demand for safe and reliable protein solutions in biopharmaceutical manufacturing and therapeutic applications is driving market expansion. Recombinant albumin is widely utilized in cell culture, drug formulation, and therapeutic protein stabilization due to its superior safety profile compared to plasma-derived albumin. As biologics and biosimilars gain traction in the global healthcare landscape, the adoption of recombinant albumin as a key excipient is witnessing significant growth.